Published in Chem Biol on January 29, 2010
Halogen-enriched fragment libraries as leads for drug rescue of mutant p53. J Am Chem Soc (2012) 1.50
Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:hypoxia inducible factor 1α protein-protein interface. Chem Biol (2012) 1.26
Solution structure and dynamic analysis of chicken MBD2 methyl binding domain bound to a target-methylated DNA sequence. Nucleic Acids Res (2011) 1.26
SCF ubiquitin ligase-targeted therapies. Nat Rev Drug Discov (2014) 1.25
The free energy landscape of small molecule unbinding. PLoS Comput Biol (2011) 1.25
Using protein design algorithms to understand the molecular basis of disease caused by protein-DNA interactions: the Pax6 example. Nucleic Acids Res (2010) 1.16
Using a fragment-based approach to target protein-protein interactions. Chembiochem (2013) 1.09
Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery. Proc Natl Acad Sci U S A (2013) 1.05
Interaction of the p53 DNA-binding domain with its n-terminal extension modulates the stability of the p53 tetramer. J Mol Biol (2011) 1.04
Oroxylin A inhibits hemolysis via hindering the self-assembly of α-hemolysin heptameric transmembrane pore. PLoS Comput Biol (2013) 1.02
Bioinformatics and variability in drug response: a protein structural perspective. J R Soc Interface (2012) 1.01
Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases. Chem Rev (2014) 0.98
Ordering a dynamic protein via a small-molecule stabilizer. J Am Chem Soc (2013) 0.97
Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain. Biochemistry (2011) 0.92
Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding. Protein Sci (2010) 0.90
The p53-MDM2/MDMX axis - A chemotype perspective. Medchemcomm (2011) 0.88
Competitive binding of a benzimidazole to the histone-binding pocket of the Pygo PHD finger. ACS Chem Biol (2014) 0.87
Rational design of small-molecule stabilizers of spermine synthase dimer by virtual screening and free energy-based approach. PLoS One (2014) 0.83
A bidirectional system for the dynamic small molecule control of intracellular fusion proteins. ACS Chem Biol (2013) 0.80
Exploiting Transient Protein States for the Design of Small-Molecule Stabilizers of Mutant p53. Structure (2015) 0.80
Enhanced interrogation: emerging strategies for cell signaling inhibition. Nat Struct Mol Biol (2010) 0.78
How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures. ChemMedChem (2015) 0.78
Creating novel activated factor XI inhibitors through fragment based lead generation and structure aided drug design. PLoS One (2015) 0.77
Selective Targeting of the TPX2 Site of Importin-α Using Fragment-Based Ligand Design. ChemMedChem (2015) 0.77
Wrapping effects within a proposed function-rescue strategy for the Y220C oncogenic mutation of protein p53. PLoS One (2013) 0.76
Driving Structure-Based Drug Discovery through Cosolvent Molecular Dynamics. J Med Chem (2016) 0.76
Hydrogen Bond Dynamic Propensity Studies for Protein Binding and Drug Design. PLoS One (2016) 0.75
An in silico algorithm for identifying stabilizing pockets in proteins: test case, the Y220C mutant of the p53 tumor suppressor protein. Protein Eng Des Sel (2016) 0.75
Exploring the potential of a structural alphabet-based tool for mining multiple target conformations and target flexibility insight. PLoS One (2017) 0.75
Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer (2009) 5.12
The complete folding pathway of a protein from nanoseconds to microseconds. Nature (2003) 3.61
The crystal structure of human CD1d with and without alpha-galactosylceramide. Nat Immunol (2005) 3.53
Principles and applications of halogen bonding in medicinal chemistry and chemical biology. J Med Chem (2013) 3.48
Structural biology of the tumor suppressor p53. Annu Rev Biochem (2008) 3.36
Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci U S A (2006) 3.35
A transient and low-populated protein-folding intermediate at atomic resolution. Science (2010) 3.08
Is there a unifying mechanism for protein folding? Trends Biochem Sci (2003) 2.63
LC3C, bound selectively by a noncanonical LIR motif in NDP52, is required for antibacterial autophagy. Mol Cell (2012) 2.41
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci U S A (2008) 2.30
Cooperative binding of tetrameric p53 to DNA. J Mol Biol (2004) 2.26
Unifying features in protein-folding mechanisms. Proc Natl Acad Sci U S A (2003) 2.24
Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain. Proc Natl Acad Sci U S A (2008) 2.14
Quaternary structures of tumor suppressor p53 and a specific p53 DNA complex. Proc Natl Acad Sci U S A (2007) 2.09
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell (2009) 2.09
Wordom: a program for efficient analysis of molecular dynamics simulations. Bioinformatics (2007) 2.05
Molecular mechanism of the interaction between MDM2 and p53. J Mol Biol (2002) 2.03
Mechanical unfolding of a titin Ig domain: structure of unfolding intermediate revealed by combining AFM, molecular dynamics simulations, NMR and protein engineering. J Mol Biol (2002) 2.00
Comparative binding of p53 to its promoter and DNA recognition elements. J Mol Biol (2005) 1.96
Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations. J Biol Chem (2003) 1.94
Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53. Proc Natl Acad Sci U S A (2007) 1.86
General structural motifs of amyloid protofilaments. Proc Natl Acad Sci U S A (2006) 1.72
Tumor suppressor p53 slides on DNA with low friction and high stability. Biophys J (2008) 1.70
Testing protein-folding simulations by experiment: B domain of protein A. Proc Natl Acad Sci U S A (2004) 1.70
Kinetic instability of p53 core domain mutants: implications for rescue by small molecules. J Biol Chem (2003) 1.68
Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. J Biol Chem (2005) 1.67
Folding and unfolding mechanism of highly stable full-consensus ankyrin repeat proteins. J Mol Biol (2007) 1.67
The central region of HDM2 provides a second binding site for p53. Proc Natl Acad Sci U S A (2006) 1.67
Direct observation of barrier-limited folding of BBL by single-molecule fluorescence resonance energy transfer. Proc Natl Acad Sci U S A (2009) 1.65
The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb Perspect Biol (2010) 1.64
The crystal structure of human CD1b with a bound bacterial glycolipid. J Immunol (2004) 1.64
Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains. J Biol Chem (2006) 1.61
Core domain interactions in full-length p53 in solution. Proc Natl Acad Sci U S A (2006) 1.59
A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci U S A (2002) 1.58
Algorithm for prediction of tumour suppressor p53 affinity for binding sites in DNA. Nucleic Acids Res (2008) 1.58
An ankyrin-repeat ubiquitin-binding domain determines TRABID's specificity for atypical ubiquitin chains. Nat Struct Mol Biol (2011) 1.55
Solution structure of p53 core domain: structural basis for its instability. Proc Natl Acad Sci U S A (2006) 1.53
Phi-analysis at the experimental limits: mechanism of beta-hairpin formation. J Mol Biol (2006) 1.53
Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor. Proc Natl Acad Sci U S A (2005) 1.52
Ultra-fast barrier-limited folding in the peripheral subunit-binding domain family. J Mol Biol (2005) 1.52
The denatured state of Engrailed Homeodomain under denaturing and native conditions. J Mol Biol (2003) 1.51
Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene (2002) 1.51
Halogen-enriched fragment libraries as leads for drug rescue of mutant p53. J Am Chem Soc (2012) 1.50
Structural evolution of p53, p63, and p73: implication for heterotetramer formation. Proc Natl Acad Sci U S A (2009) 1.46
A single-molecule characterization of p53 search on DNA. Proc Natl Acad Sci U S A (2010) 1.43
Sequential unfolding of ankyrin repeats in tumor suppressor p16. Structure (2003) 1.43
Direct observation of ultrafast folding and denatured state dynamics in single protein molecules. Proc Natl Acad Sci U S A (2009) 1.39
14-3-3 activation of DNA binding of p53 by enhancing its association into tetramers. Nucleic Acids Res (2008) 1.36
Distinguishing between cooperative and unimodal downhill protein folding. Proc Natl Acad Sci U S A (2007) 1.35
Rapid amyloid fiber formation from the fast-folding WW domain FBP28. Proc Natl Acad Sci U S A (2003) 1.33
Binding of Rad51 and other peptide sequences to a promiscuous, highly electrostatic binding site in p53. J Biol Chem (2004) 1.31
Early events in protein folding. Curr Opin Struct Biol (2003) 1.28
Correlation of levels of folded recombinant p53 in escherichia coli with thermodynamic stability in vitro. J Mol Biol (2007) 1.27
Simulation and experiment conspire to reveal cryptic intermediates and a slide from the nucleation-condensation to framework mechanism of folding. J Mol Biol (2005) 1.27
Modulation of the oligomerization state of p53 by differential binding of proteins of the S100 family to p53 monomers and tetramers. J Biol Chem (2009) 1.25
Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res (2013) 1.24
One-state downhill versus conventional protein folding. J Mol Biol (2004) 1.24
Dishevelled interacts with the DIX domain polymerization interface of Axin to interfere with its function in down-regulating β-catenin. Proc Natl Acad Sci U S A (2011) 1.24
The helix-turn-helix motif as an ultrafast independently folding domain: the pathway of folding of Engrailed homeodomain. Proc Natl Acad Sci U S A (2007) 1.23
Comparative biophysical characterization of p53 with the pro-apoptotic BAK and the anti-apoptotic BCL-xL. J Biol Chem (2007) 1.23
Recognition of DNA by p53 core domain and location of intermolecular contacts of cooperative binding. J Mol Biol (2002) 1.22
Regulation of DNA binding of p53 by its C-terminal domain. J Mol Biol (2004) 1.22
Demonstration of a low-energy on-pathway intermediate in a fast-folding protein by kinetics, protein engineering, and simulation. Proc Natl Acad Sci U S A (2004) 1.21
Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition. Proc Natl Acad Sci U S A (2012) 1.21
Single-Molecule characterization of oligomerization kinetics and equilibria of the tumor suppressor p53. Nucleic Acids Res (2010) 1.20
Carboxyl pK(a) values and acid denaturation of BBL. J Mol Biol (2010) 1.20
Binding of natively unfolded HIF-1alpha ODD domain to p53. Mol Cell (2005) 1.18
Two sequence motifs from HIF-1alpha bind to the DNA-binding site of p53. Proc Natl Acad Sci U S A (2002) 1.18
Physical and functional interactions between human mitochondrial single-stranded DNA-binding protein and tumour suppressor p53. Nucleic Acids Res (2008) 1.18
CRINEPT-TROSY NMR reveals p53 core domain bound in an unfolded form to the chaperone Hsp90. Proc Natl Acad Sci U S A (2002) 1.17
Acetylation of lysine 120 of p53 endows DNA-binding specificity at effective physiological salt concentration. Proc Natl Acad Sci U S A (2011) 1.16
Conservation of DNA-binding specificity and oligomerisation properties within the p53 family. BMC Genomics (2009) 1.16
Conformational entropy of alanine versus glycine in protein denatured states. Proc Natl Acad Sci U S A (2007) 1.13
Multiple conformations of full-length p53 detected with single-molecule fluorescence resonance energy transfer. Proc Natl Acad Sci U S A (2009) 1.13
Biophysical characterizations of human mitochondrial transcription factor A and its binding to tumor suppressor p53. Nucleic Acids Res (2009) 1.13
Sequence-dependent sliding kinetics of p53. Proc Natl Acad Sci U S A (2012) 1.13
An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid. Nat Commun (2012) 1.11
A structural double-mutant cycle: estimating the strength of a buried salt bridge in barnase. Acta Crystallogr D Biol Crystallogr (2002) 1.10
The structure of the major transition state for folding of an FF domain from experiment and simulation. J Mol Biol (2005) 1.10
The kinetic pathway of folding of barnase. J Mol Biol (2003) 1.09
Hydrophobic core fluidity of homologous protein domains: relation of side-chain dynamics to core composition and packing. Biochemistry (2004) 1.08
Electron microscopy studies on the quaternary structure of p53 reveal different binding modes for p53 tetramers in complex with DNA. Proc Natl Acad Sci U S A (2010) 1.08
The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. J Mol Biol (2002) 1.08
Structural biology of the tumor suppressor p53 and cancer-associated mutants. Adv Cancer Res (2007) 1.07